Molecular structure of Dipyridamole-D20 (Major)
Dipyridamole-D20 (Major) (CAS 58-32-2 unlabeled)
Alternate Names:
Anginal-d20; Cardoxin-d20; Cleridium-d20; Dipyridan-d20; Natyl-d20; Peridamol-d20
Application:
Dipyridamole-D20 (Major) is a selective phosphodiesterase V (PDE 5) inhibitor
CAS Number:
58-32-2 unlabeled
Molecular Weight:
524.75
Molecular Formula:
C24H20D20N8O4
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Dipyridamole-D20 (Major) is a deuterium labeled derivative of Dipyridamole, which has been shown to act as a selective inhibitor of phosphodiesterase V (PDE 5). This compound has been shown to suppress high glucose-induced osteopontin mRNA expression and protein secretion, as well as inhibit cAMP and cGMP hydrolysis. Research indicates that Dipyridamole is a non-specific nucleoside transport inhibitor with the ability to increase the effects of adenosine in sinoatrial and atrioventricular nodes.
Dipyridamole-D20 (Major) (CAS 58-32-2 unlabeled) References
- Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). | Fujishige, K., et al. 1999. J Biol Chem. 274: 18438-45. PMID: 10373451
- Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. | Lugnier, C. 2006. Pharmacol Ther. 109: 366-98. PMID: 16102838
- Dipyridamole suppresses high glucose-induced osteopontin secretion and mRNA expression in rat aortic smooth muscle cells. | Hsieh, MS., et al. 2010. Circ J. 74: 1242-50. PMID: 20453393
- Effect of dipyridamole on myocardial reperfusion injury: A double-blind randomized controlled trial in patients undergoing elective coronary artery bypass surgery. | El Messaoudi, S., et al. 2016. Clin Pharmacol Ther. 99: 381-9. PMID: 25773594
- Removal characteristics of pharmaceuticals and personal care products: Comparison between membrane bioreactor and various biological treatment processes. | Park, J., et al. 2017. Chemosphere. 179: 347-358. PMID: 28384602
- Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets. Isolation, characterization, and effects of various reference phosphodiesterase inhibitors and cardiotonic agents. | Weishaar, RE., et al. 1986. Biochem Pharmacol. 35: 787-800. PMID: 3006691
- The effect of the nucleoside transport inhibitor dipyridamole on the incorporation of [3H]thymidine in the rat. | Newell, DR., et al. 1986. Biochem Pharmacol. 35: 3871-7. PMID: 3778511
- Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase. | Soderling, SH., et al. 1998. Proc Natl Acad Sci U S A. 95: 8991-6. PMID: 9671792
- Pharmacological analysis of the activity of the adenosine uptake inhibitor, dipyridamole, on the sinoatrial and atrioventricular nodes of the guinea-pig. | Meester, BJ., et al. 1998. Br J Pharmacol. 124: 729-41. PMID: 9690865
Inhibitor of:
PDE.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Dipyridamole-D20 (Major), 1 mg | sc-218245 | 1 mg | $330.00 |